In tablet and bolus manufacture, the tincture is introduced as a non-aqueous granulating fluid at 4.0–8.5% w/w of dry blend, replacing water in formulations containing moisture-labile vitamins, enzyme premixes, or hygroscopic mineral salts. The granulation end-point is assessed by pressing the wet mass through a 1.6 mm screen in a high-shear granulator operated at 40–60 rpm impeller speed; over-wetting beyond 9.0% w/w generates agglomerates with >2.0 mm size and raises impeller torque by 18–25%. The wet granules are transferred to a fluid-bed dryer and dried at 35–40 °C until residual ethanol is ≤5,000 ppm, consistent with Class 3 solvent limits in VICH GL18. The wax component melts between 61–65 °C under Ph. Eur. monograph 0070, but compression tooling is maintained below 45 °C to prevent surface migration and punch filming. For a 12 mm flat-faced veterinary bolus, a 10-station rotary press operates at 8–14 kN compression force, yielding tablet breaking force of 80–120 N and friability ≤0.8% by Ph. Eur. 2.9.7. Release testing in 0.1 M HCl with 0.5% sodium lauryl sulfate at 37 ± 0.5 °C and 50 rpm paddle speed under USP <711> shows 80% release deferred to 6–10 h at 6.0–8.5% w/w tincture inclusion, compared with 45–60 min for the same granulate without wax. The relationship is non-linear: above 9.0% w/w, breaking force can exceed 150 N while dissolution slows to >12 h, creating mechanical-rupture dose-dumping risks in fasted preruminant calves. On production-scale presses, ejection force rises by 12–18% when the tincture is added as a hot melt rather than sprayed as an ethanolic solution; 0.5% w/w calcium stearate is typically added to keep ejection force below 1,200 N. A hydroxypropyl methylcellulose film coating is applied in a side-vented pan with inlet air at 60–65 °C and tablet-bed temperature at 42–46 °C to prevent wax bloom on the tablet surface.

Values are representative range-finding data from a 10-station rotary press with 12 mm flat-faced tooling; they do not replace site-specific process validation.

What Limits Sterile Filtration When Beeswax Tincture Is Used in Oleaginous Veterinary Depot Vehicles?

For oleaginous depot vehicles, the tincture is pre-dried under vacuum at 40 °C until water content is ≤0.3% w/w, because free water accelerates ester hydrolysis and complicates endotoxin recovery. The dried material is dissolved in medium-chain triglycerides or ethyl oleate at 2.0–6.0% w/w under nitrogen at 55–60 °C; the melt is then cooled to 45–50 °C for filtration through a 0.45 µm PVDF membrane. At 6.0% w/w, dynamic viscosity measured at 40 °C in a rotational viscometer typically reaches 80–120 mPa·s, requiring a 1.0 µm glass-fibre pre-filter to avoid blinding of the sterilising membrane. Terminal moist-heat sterilisation at 121 °C for 30 min is problematic for wax-structured depot formulations because the wax phase melts and can coalesce on cooling; published data for this specific configuration under terminal sterilisation are limited, and most lines instead rely on aseptic filtration of the molten vehicle. If a terminal heat cycle is unavoidable, the filled containers should be cooled at 0.5–1.0 °C/min under slow axial rotation to below 35 °C, and batch records should document the absence of visible wax aggregates by Ph. Eur. 2.9.20. Ethanol content after dissolution and filtration is reduced below 5,000 ppm by vacuum distillation at 40–45 °C; residual solvent testing follows VICH GL18 headspace GC with flame ionisation detection. The tincture should not be combined with amine-based alkalising agents in the molten vehicle because free amine groups can accelerate ester saponification when the wax acid value exceeds 17 mg KOH/g. Filtration and filling are conducted in an aseptic processing line qualified under 21 CFR 211.167 and Ph. Eur. 2.6.1. Endotoxin specification is product-specific under Ph. Eur. 2.6.14; no universal parenteral limit applies across all veterinary depot presentations.

Capsule filling with this material requires granulation rather than direct liquid filling when excipient compatibility limits ethanol contact to ≤0.5% w/w. Non-aqueous granulation is performed with lactose monohydrate and microcrystalline cellulose as bulking agents; the tincture at 2–4% w/w is sprayed into the powder bed over 60–120 s in a high-shear granulator, and the wet mass is passed through a 1.0 mm conical sieve before drying at 35 °C to a moisture content ≤4.0%. The granulate is filled into size 1 or 0 hard gelatin or HPMC capsules at 350–550 mg target fill weight on a dosator-type capsule machine. Dissolution under USP <711> Apparatus II at 50 rpm in 0.1 M HCl with 0.5% sodium lauryl sulfate typically releases 55–75% of the marker at 6 h, but the range narrows when the tincture acid value is controlled to 17–24 mg KOH/g by Ph. Eur. monograph 0070. Capsule shells stored above 60% RH soften and can adhere to wax-coated granules, so bulk and packaged stability zones are maintained at 25 °C/60% RH or 40 °C/75% RH for stress testing only. The main production bottleneck is granulate flow: wax-coated particles with median particle size 180–250 µm can carry electrostatic charge after low-humidity drying, requiring 0.1% w/w colloidal silicon dioxide and 45–55% RH in the filling suite to keep capsule weight variation within ±5%.

Dry Powder Carriers and Dust Control in Medicated Premix Lines

A 0.5–1.5% w/w spray-coating step onto calcium carbonate or precipitated silica carrier particles is used before addition of the active premix in a ploughshare mixer operating at 25–30 °C. After evaporation of ethanol, the wax forms discontinuous films on carrier surfaces; dustiness measured by the rotating-drum method in DIN 55992-2 is reduced by 70–85% relative to untreated carrier. The coated carrier is immediately blended with the remaining microingredients in a V-blender or container blender at 15–25 rpm for 10–15 min. Blending uniformity is assessed by taking 10 stratified samples and testing the active marker with USP <905> or Ph. Eur. 2.9.40; acceptance is a relative standard deviation ≤5.0%. Because the tincture contains ethanol, mixing equipment installed in European facilities is operated under ATEX 2014/34/EU zone classification when the vapour concentration can exceed 20% of the lower explosive limit. The terminal powder product is discharged through a 500 µm safety sieve to remove wax agglomerates formed when spray pressure falls below 2.0 bar or nozzle temperature drops below 20 °C. The main limitation is that wax carrier coating is not compatible with subsequent moist heat pelleting above 65 °C because the coating melts and can cause die plugging in feed mills.

When Melt-Bound Granulation Replaces Aqueous Wet Granulation for Moisture-Labile Veterinary Granules

When the tincture is employed as a melt-bound granulation fluid, the high-shear mixer jacket is held at 58–62 °C so that ethanol flashes off while the wax phase remains molten and binds the powder bed. Tincture addition at 3.0–5.0% w/w is completed over 45–90 s, and massing continues for 90–180 s; the granulation is then cooled rapidly in a fluid-bed cooler to 20–25 °C to congeal the wax bridges. The cooled granules are screened through a 1.0–2.0 mm oscillating sieve. This route is applied to moisture-labile actives such as live yeast, probiotic spores, coated vitamin A or D₃, and enzyme concentrates, where aqueous granulation would reduce potency or create sticky granule beds. The process window is narrow: jacket temperature below 58 °C leaves undried ethanol and soft granules, while above 65 °C accelerates oxidation of the wax, raising acid value and deepening colour. Residual ethanol after cooling should be ≤5,000 ppm per VICH GL18. Granule friability is checked by sieve analysis after 10 min in a fluidised bed at 25 m/s air velocity; mass loss below 1.0% is considered acceptable for bulk feed top-dressing. Published data for this specific configuration in twin-screw melt granulation are limited, so scale-up from high-shear to continuous twin-screw equipment requires re-qualification of the thermal profile and screw speed.

Premix production lines handling vitamin-mineral blends achieve better carrier adhesion when the tincture is applied as a 0.75–1.25% w/w spray onto sepiolite or limestone before addition of microingredients. The spray step is performed in a double-shaft paddle mixer at 25–30 °C with chopper speed 1,500–2,000 rpm for 2–3 min; subsequent addition of vitamin A, vitamin D₃, trace minerals, and choline chloride is followed by 8–10 min of dry blending. Homogeneity sampling from 10 locations using a stratified thief yields a coefficient of variation ≤5% for vitamin A acetate as determined by HPLC following USP <905>. The wax film reduces absorption of atmospheric moisture by choline chloride and improves flowability through 10 mm auger dosing systems in feed mills. Table 2 summarises the relevant compliance boundary for this application.

What Phase Behaviour Should Be Checked Before Diluting the Tincture into Aqueous Veterinary Dosing Solutions?

Aqueous dilution trials with the ethanolic tincture should begin with co-solvent screening because direct dilution into water below 25% v/v ethanol frequently produces a cloudy microdispersion rather than a true solution. The tincture is first combined with propylene glycol or glycerol formal at 10–25% v/v and mixed under overhead stirring at 300–500 rpm; the aqueous phase is then added at 20–25 °C at a rate not exceeding 5% of batch volume per minute. Cloud point is measured by cooling the solution at 0.5 °C/min in a programmable bath; if clouding occurs above 5 °C, the co-solvent ratio is increased or a non-ionic surfactant such as polysorbate 80 is added at 0.1–0.5% w/w. Final pH is maintained between 4.0–7.0 because alkaline conditions above pH 9 promote saponification of wax esters, raising free fatty acid content and producing crystalline precipitates. The finished solution is clarified through 10 µm polypropylene depth media and, for ophthalmic or intramammary products, through 0.45 µm membranes before filling. Viscosity measured by rotational viscometer at 25 °C typically falls between 15–40 mPa·s. Film-drying time on glass slides under 25 °C/60% RH air flow is 5–15 min, which allows controlled deposition of lipophilic actives in pour-on or spot-on presentations. Packaging in HDPE bottles with induction-sealed closures is preferred over low-density polyethylene because ethanol permeability through LDPE causes weight loss and shifts co-solvent balance over shelf life. The main incompatibility is with strong oxidising disinfectants such as hypochlorite or hydrogen peroxide, which should not be combined in the same container or dosing line without compatibility data on peroxide value and wax oxidation.